Abstract
Several studies have indicated that the D2 dopamine receptors mediate the antidopaminergic activity of the neuroleptics; nevertheless, the selective blocker (−)-sulpiride weakly inhibits dopamine-mediated behaviour. The present study investigated whether the concomitant injection of doses of the D1 antagonist SCH 23390, which by themselves are without effect, would enable (−)-sulpiride to express fully neuroleptic activity in the rat. The benzamide YM 09151-2 that strongly inhibits dopamine-mediated behaviour was also studied. Rats receiving different doses of (−)-sulpiride, YM 09151-2 and SCH 23390 given alone or in combination were tested for exploratory activity, apomorphine-induced stereotyped behaviour and hyperactivity elicited by the D2 agonist LY 171555. When given alone, (−)-sulpiride (10, 20 and 40 mg/kg IP) had no effect on exploratory activity and stereotypy. When (−)-sulpiride was administered in combination with an ineffective dose of SCH 23390 (5 μg/kg) both responses were significantly inhibited. The combined administration of subthreshold doses of (−)-sulpiride (2.5 mg/kg) and SCH 23390 (2.5 μg/kg) significantly inhibited hypermotility induced by LY 171555. Moreover, the combined administration of ineffective doses of YM 09151-2 with subthreshold doses of SCH 23390 strongly inhibited all the behavioural responses. The results indicate that SCH 23390 allowed (−)-sulpiride to exhibit a wider spectrum of neuroleptic activity and potentiated the antidopaminergic activity of YM 09151-2.
Similar content being viewed by others
References
Arnt J (1985a) Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity. Naunyn-Schmiedeberg's Arch Pharmacol 330:97–104
Arnt J (1985b) Behavioral stimulation is induced by separate D1 and D2 receptor sites in reserpine-pretreated but not in normal rats. Eur J Pharmacol 113:79–88
Arnt J, Hyttel J, Perregaard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur J Pharmacol 133:137–145
Benakis A, Pongis MA, Sugnaux F, Vitus J (1976) Localization, distribution, elimination, metabolism and pharmacokinetics of 14C-Sulpiride in rats. Eur J Drug Metab Pharmacokinet 1:51–62
Breese GR, Mueller RA (1985) SCH 23390 antagonism of a D-2 dopamine agonist depend upon catecholaminergic neurons. Eur J Pharmacol 113:109–114
Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34:1529–1540
Costall B, Naylor RJ (1975) Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia 43:69–74
Costall B, Kelly ME, Naylor RJ (1983) The production of asymmetry and circling behaviour following unilateral, intrastriatal administration of neuroleptic agents: a comparison of abilities to antagonize striatal function. Eur J Pharmacol 96:79–86
Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483
Dall'Olio R, Gandolfi O, Vaccheri A, Roncada P, Montanaro N (1988) Changes in behavioural responses to the combined administration of D1 and D2 dopamine agonists in normosensitive and D1 supersensitive rats. Psychopharmacology 95:381–385
Gandolfi O, Dall'Olio R, Vaccheri A, Roncada P, Montanaro N (1988) Responses to selective D-1 and D-2 agonists after repeated treatment with selective D-1 and D-2 antagonists. Pharmacol Biochem Behav 30:463–469
Honda F, Satoh Y, Shimomura K, Satoh H, Noguchi H, Uchida H, Kato R (1977) Dopamine receptor blocking activity of sulpiride in the central nervous system. Jpn J Pharmacol 27:397–411
Iorio LC, Barnett A, Leitz F, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic system. J Pharmacol Exp Ther 226:462–468
Jenner P, Clow A, Reavill C, Theodorou A, Marsden CD (1978) A behavioral and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs. Life Sci 23:545–550
Mashurano M, Waddington JL (1986) Stereotyped behavior in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SKF 38393. Neuropharmacology 25:947–949
Mielke DH, Gallant DM, Kessler C (1977) An evaluation of a unique new antipsychotic agent sulpiride: effects on serum prolactin and growth hormone levels. Am J Psychiatry 134:1371–1375
Molloy AG, O'Boyle KM, Pugh MT, Waddington JL (1986) Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists. Pharmacol Biochem Behav 25:249–253
Montanaro N, Dall'Olio R, Gandolfi O, Vaccheri A (1982) Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (−)-sulpiride and haloperidol. Eur J Pharmacol 81:1–9
Pugh MT, O'Boyle KM, Molloy AG, Waddington JL (1985) Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU 24213. Psychopharmacology 87:308–312
Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32:229–313
Serra G, Van Ree JM, De Vied D (1983) Influence of classical and atypical neuroleptics on apomorphine-induced behavioural changes on extinction of a conditioned avoidance response. J Pharma Pharmacol 35:255–257
Usuda S, Nishikori K, Noshiro O, Maeno H (1981) Neuroleptic properties of cis-N-(1-benzyl-2-methylpirrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM 09151-2) with selective antidopaminergic activity. Psychopharmacology 73:103–109
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dall'Olio, R., Roncada, P., Vaccheri, A. et al. Synergistic blockade of some dopamine-mediated behaviours by (−)-sulpiride and SCH 23390 in the rat. Psychopharmacology 98, 342–346 (1989). https://doi.org/10.1007/BF00451685
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00451685